Genomic  ||| S:0 E:8 ||| JJ
basis  ||| S:8 E:14 ||| NN
for  ||| S:14 E:18 ||| IN
breast  ||| S:18 E:25 ||| JJ
cancer ||| S:25 E:31 ||| NN
:  ||| S:31 E:33 ||| :
advances  ||| S:33 E:42 ||| NNS
in  ||| S:42 E:45 ||| IN
personalized  ||| S:45 E:58 ||| JJ
medicine  ||| S:58 E:67 ||| NN
Genomic  ||| S:67 E:75 ||| NNP
analysis  ||| S:75 E:84 ||| NN
of  ||| S:84 E:87 ||| IN
breast  ||| S:87 E:94 ||| JJ
cancer  ||| S:94 E:101 ||| NN
has  ||| S:101 E:105 ||| VBZ
allowed  ||| S:105 E:113 ||| VBN
the  ||| S:113 E:117 ||| DT
development  ||| S:117 E:129 ||| NN
of  ||| S:129 E:132 ||| IN
new  ||| S:132 E:136 ||| JJ
tools  ||| S:136 E:142 ||| NNS
for  ||| S:142 E:146 ||| IN
the  ||| S:146 E:150 ||| DT
prediction  ||| S:150 E:161 ||| NN
of  ||| S:161 E:164 ||| IN
recurrence  ||| S:164 E:175 ||| NN
and  ||| S:175 E:179 ||| CC
the  ||| S:179 E:183 ||| DT
response  ||| S:183 E:192 ||| NN
to  ||| S:192 E:195 ||| TO
treatment  ||| S:195 E:205 ||| NN
of  ||| S:205 E:208 ||| IN
this  ||| S:208 E:213 ||| DT
disease ||| S:213 E:220 ||| NN
.  ||| S:220 E:222 ||| .
Gene  ||| S:222 E:227 ||| NN
expression  ||| S:227 E:238 ||| NN
profiles  ||| S:238 E:247 ||| NNS
allow  ||| S:247 E:253 ||| VBP
better  ||| S:253 E:260 ||| JJR
tumor  ||| S:260 E:266 ||| NN
classification ||| S:266 E:280 ||| NN
,  ||| S:280 E:282 ||| ,
identifying  ||| S:282 E:294 ||| VBG
tumor  ||| S:294 E:300 ||| NN
subgroups  ||| S:300 E:310 ||| NNS
with  ||| S:310 E:315 ||| IN
particular  ||| S:315 E:326 ||| JJ
clinical  ||| S:326 E:335 ||| JJ
outcomes ||| S:335 E:343 ||| NNS
.  ||| S:343 E:345 ||| .
New  ||| S:345 E:349 ||| JJ
potential  ||| S:349 E:359 ||| JJ
molecular  ||| S:359 E:369 ||| JJ
targets  ||| S:369 E:377 ||| NNS
involved  ||| S:377 E:386 ||| VBN
in  ||| S:386 E:389 ||| IN
breast  ||| S:389 E:396 ||| JJ
carcinogenesis  ||| S:396 E:411 ||| NNS
have  ||| S:411 E:416 ||| VBP
also  ||| S:416 E:421 ||| RB
been  ||| S:421 E:426 ||| VBN
identified  ||| S:426 E:437 ||| VBN
through  ||| S:437 E:445 ||| IN
the  ||| S:445 E:449 ||| DT
analysis  ||| S:449 E:458 ||| NN
of  ||| S:458 E:461 ||| IN
DNA  ||| S:461 E:465 ||| NNP
copy  ||| S:465 E:470 ||| NN
number  ||| S:470 E:477 ||| NN
aberrations  ||| S:477 E:489 ||| NNS
and  ||| S:489 E:493 ||| CC
microRNA  ||| S:493 E:502 ||| JJ
expression  ||| S:502 E:513 ||| NN
patterns ||| S:513 E:521 ||| NNS
.  ||| S:521 E:523 ||| .
Whole  ||| S:523 E:529 ||| JJ
genome  ||| S:529 E:536 ||| JJ
association  ||| S:536 E:548 ||| NN
studies  ||| S:548 E:556 ||| NNS
have  ||| S:556 E:561 ||| VBP
identified  ||| S:561 E:572 ||| VBN
genetic  ||| S:572 E:580 ||| JJ
variants  ||| S:580 E:589 ||| NNS
associated  ||| S:589 E:600 ||| VBN
with  ||| S:600 E:605 ||| IN
a  ||| S:605 E:607 ||| DT
higher  ||| S:607 E:614 ||| JJR
risk  ||| S:614 E:619 ||| NN
to  ||| S:619 E:622 ||| TO
develop  ||| S:622 E:630 ||| VB
this  ||| S:630 E:635 ||| DT
tumor ||| S:635 E:640 ||| NN
,  ||| S:640 E:642 ||| ,
providing  ||| S:642 E:652 ||| VBG
more  ||| S:652 E:657 ||| JJR
information  ||| S:657 E:669 ||| NN
for  ||| S:669 E:673 ||| IN
public  ||| S:673 E:680 ||| JJ
health  ||| S:680 E:687 ||| NN
decisions ||| S:687 E:696 ||| NNS
.  ||| S:696 E:698 ||| .
Progress  ||| S:698 E:707 ||| NN
in  ||| S:707 E:710 ||| IN
DNA  ||| S:710 E:714 ||| NNP
sequencing  ||| S:714 E:725 ||| NN
methods  ||| S:725 E:733 ||| NNS
will  ||| S:733 E:738 ||| MD
also  ||| S:738 E:743 ||| RB
allow  ||| S:743 E:749 ||| VB
for  ||| S:749 E:753 ||| IN
the  ||| S:753 E:757 ||| DT
analysis  ||| S:757 E:766 ||| NN
of  ||| S:766 E:769 ||| IN
all  ||| S:769 E:773 ||| PDT
the  ||| S:773 E:777 ||| DT
genetic  ||| S:777 E:785 ||| JJ
alterations  ||| S:785 E:797 ||| JJ
present  ||| S:797 E:805 ||| NN
in  ||| S:805 E:808 ||| IN
a  ||| S:808 E:810 ||| DT
tumor ||| S:810 E:815 ||| NN
.  ||| S:815 E:817 ||| .
In  ||| S:817 E:820 ||| IN
this  ||| S:820 E:825 ||| DT
review ||| S:825 E:831 ||| NN
,  ||| S:831 E:833 ||| ,
we  ||| S:833 E:836 ||| PRP
describe  ||| S:836 E:845 ||| VBP
the  ||| S:845 E:849 ||| DT
current  ||| S:849 E:857 ||| JJ
state  ||| S:857 E:863 ||| NN
of  ||| S:863 E:866 ||| IN
genomic  ||| S:866 E:874 ||| JJ
research  ||| S:874 E:883 ||| NN
in  ||| S:883 E:886 ||| IN
breast  ||| S:886 E:893 ||| JJ
cancer  ||| S:893 E:900 ||| NN
as  ||| S:900 E:903 ||| IN
well  ||| S:903 E:908 ||| RB
as  ||| S:908 E:911 ||| IN
how  ||| S:911 E:915 ||| WRB
these  ||| S:915 E:921 ||| DT
findings  ||| S:921 E:930 ||| NNS
are  ||| S:930 E:934 ||| VBP
being  ||| S:934 E:940 ||| VBG
translated  ||| S:940 E:951 ||| VBN
into  ||| S:951 E:956 ||| IN
clinical  ||| S:956 E:965 ||| JJ
practice ||| S:965 E:973 ||| NN
,  ||| S:973 E:975 ||| ,
contributing  ||| S:975 E:988 ||| VBG
to  ||| S:988 E:991 ||| TO
development  ||| S:991 E:1003 ||| NN
of  ||| S:1003 E:1006 ||| IN
personalized  ||| S:1006 E:1019 ||| JJ
medicine ||| S:1019 E:1027 ||| NN
.  ||| S:1027 E:1029 ||| .
